The Labeling of Adriamycin-loaded Human Serum Albumin Immunonanoparticles Led by Monoclonal Antibodies With ~(131)I and Its Anti-hepatoma Effect in Vivo

The pharmaceutics character, targeting to hepatoma and anticancer activity in nude mice of adriamycinloaded human serum albumin immunonanoparticles (ADRHSANP) against hepatoma led by antihuman hepatoma monoclonal antibodies HAb18 are studied. The results show that effective loaded drug dose of HAb18ADRHSANP is 1.44%, which is lower than ADRHSANP(1.69%); HAb18ADRHSANP slowly releases drug ADR and its maximum releasing drug dose(41%)is obviously lower than ADRHSANP(65%) (P<0.05); nowever, 131IHAb18ADRHSANP mainly accumulates in liver and its liertaxis and stability are better than 131IADRHSANP in nude mice by intravenous injection; HAb18ADRHSANP mainly accumulates in tumor and its accumulation amount of tumor is higher than ADRHSANP(P<0.05), and has obvious inhibiting cancer action and its inhibitory rate of cancer is also higher than ADRHSANP(P<0.05) by tumor injection. So, HAb18ADRHSANP can bind and inhibit hepatoma cell from growing in vivo.